

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL LLC AND PFIZER INC.,
Petitioners,

v.

NOVO NORDISK A/S,
Patent Owner.

Case IPR2020-00324¹
Patent 8,114,833

PATENT OWNER SUR-REPLY

¹ IPR2020-01252 has been joined with this proceeding.

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. GROUND 1: FLINK DOES NOT ANTICIPATE CLAIMS 1-15	4
A. Flink Does Not Lead a Skilled Artisan To “Immediately Envision” the Claimed Formulations	4
B. Consideration of Flink as a “Whole,” Shows There Is No Anticipation	6
C. The Remainder of Petitioner’s Arguments Do Not Advance Its Anticipation Theory	7
III. GROUND 2: CLAIMS 1-15 WOULD NOT HAVE BEEN OBVIOUS OVER FLINK.....	9
A. Petitioner Has Not Shown a Motivation to Combine, Nor a Reasonable Expectation of Success	9
B. Novo Nordisk’s Interpretation of Flink’s Disclosure Is Correct	11
IV. THE PREAMBLES OF CLAIMS 23-31 ARE LIMITING.....	11
V. CLAIMS 1-31 WOULD NOT HAVE BEEN OBVIOUS OVER FLINK IN VIEW OF BETZ.....	13
VI. BETZ IS NOT PRIOR ART TO THE ’833 PATENT.....	16
VII. NOVO NORDISK REDUCED THE CLAIMED INVENTIONS TO PRACTICE BY AT LEAST [REDACTED]	17
VIII. SECONDARY CONSIDERATIONS STRONGLY REFUTE ANY SHOWING OF OBVIOUSNESS.....	20
IX. DR. FORREST’S REPLY DECLARATION IS IMPROPER.....	23
X. CONCLUSION.....	25

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Allergan, Inc. v. Sandoz Inc.</i> , 796 F.3d 1293 (Fed. Cir. 2015)	16, 21
<i>Boehringer Ingelheim Vetmedica, Inc. v. Schering-Plough Corp.</i> , 320 F.3d 1339 (Fed. Cir. 2003)	12
<i>Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc.</i> , 752 F.3d 967 (Fed. Cir. 2014)	20
<i>Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc.</i> , 769 F.3d 1339 (Fed. Cir. 2014)	22
<i>Complex Innovations, LLC v. AstraZeneca AB</i> , IPR2017-00631, Paper No. 13 (P.T.A.B. July 24, 2017)	6
<i>Dynamic Drinkware, LLC v. Nat’l Graphics, Inc.</i> , 800 F.3d 1375 (Fed. Cir. 2015)	17
<i>Eaton Corp. v Rockwell Int’l Corp.</i> , 323 F.3d 1332 (Fed. Cir. 2003)	12
<i>Genetics Inst., LLC v. Novartis Vaccines & Diagnostics, Inc.</i> , 655 F.3d 1291 (Fed. Cir. 2011)	22
<i>Google LLC v. Koninklijke Philips N.V.</i> , 789 Fed. App’x 874 (Fed. Cir. 2019)	17
<i>Griffin v. Bertina</i> , 285 F.3d 1029 (Fed. Cir. 2002)	12
<i>Henny Penny Corp. v. Frymaster LLC</i> , 938 F.3d 1324 (Fed. Cir. 2019)	17
<i>In re Huai-Hung Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	22

In re Kotzab,
217 F.3d 1365 (Fed. Cir. 2000)9

In re Peterson,
315 F.3d 1325 (Fed. Cir. 2003)22

In re Stepan Co.,
868 F.3d 1342 (Fed. Cir. 2017)9

Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd.,
821 F.3d 1359 (Fed. Cir. 2016)*passim*

Lupin Ltd. v. Senju Pharm. Co., Ltd.,
IPR2015-01099, Paper 69 (P.T.A.B. Sept. 12, 2016)..... 15, 25

MoneyIN, Inc. v. VeriSign, Inc.,
545 F.3d 1359 (Fed. Cir. 2008) 1

Orexo AB v. Actavis Elizabeth LLC,
903 F.3d 1265 (Fed. Cir. 2018)21

Perricone v. Medicis Pharm. Corp.,
432 F.3d 1368 (Fed. Cir. 2005)5

SmithKline Beecham Corp. v. Apotex Corp.,
403 F.3d 1331 (Fed. Cir. 2005)8

Toyota Motor Corp. v. Am. Vehicular Sci. LLC,
IPR2013-00424, Paper 50 (P.T.A.B. Jan. 12, 2015)23

STATUTES AND RULES

37 C.F.R. 42.2213, 14, 17, 23

35 U.S.C. § 312(a)(3)..... 13, 23

TABLE OF EXHIBITS

EXHIBIT	DESCRIPTION
2001	Declaration of Ryan P. Johnson in Support of Patent Owner's Motion for Admission <i>Pro Hac Vice</i> of Ryan P. Johnson Under 37 C.F.R. § 42.10(c)
2002	Declaration of Laura T. Moran in Support of Patent Owner's Motion for Admission <i>Pro Hac Vice</i> of Laura T. Moran Under 37 C.F.R. § 42.10(c)
2003	Chien-Hua Niu, <i>FDA Perspective on Peptide Formulation and Stability Issues</i> , 87 J. PHARM. SCIENCES 1331 (1998) ("Niu")
2004	C. Goolcharran, et al., <i>Chemical Pathways of Peptide and Protein Degradation</i> , in PHARMACEUTICAL FORMULATION DEVELOPMENT OF PEPTIDES AND PROTEINS 70 (Sven Frokjaer & Lars Hovgaard eds.,2000) ("Goolcharran")
2005	Mark C. Manning et al., <i>Stability of Protein Pharmaceuticals</i> , 6 PHARM. RESEARCH 903 (1989) ("Manning")
2006	R.W. Payne, et al., <i>Peptide Formulation: Challenges and Strategies</i> , INNOVATIONS PHARM. TECH. 64 (2009) ("Payne")
2007	E.T. Kaiser et al., <i>Secondary structures of proteins and peptides in amphiphilic environments (A Review)</i> , 80 PROC. NATL. ACAD. SCI. USA 1137 (1983) ("Kaiser")
2008	Dean K. Clodfelter et al., <i>Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide</i> , 15 PHARM. RES. 254 (1998) ("Clodfelter")
2009	Eva Y. Chi et al., <i>Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation</i> , 20 PHARM. RESEARCH 1325 (2003) ("Chi")
2010	U.S. Patent No. 5,932,547
2011	Lotte Knudsen, et al., <i>Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration</i> , 43 J. MED. CHEM. 1664 (2000) ("Knudsen 2000")
2012	U.S. Patent Application Publication No. 2002/0061838
2013	Humira® Package Insert (revised 01/2003)
2014	Norditropin® Approved Labeling (revised 05/2000)
2015	<i>United States Pharmacopeia and National Formulary (USP 26-NF 21) 2003</i> ("USP 2003")
2016	Alfred Doenicke, et al., <i>Osmolalities of Propylene Glycol-Containing Drug Formulations for Parenteral Use. Should Propylene Glycol Be Used as a Solvent?</i> , 75 ANESTH. ANALG. 431

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.